Attovia Therapeutics To Participate In Upcoming Investor Conferences
Citi's 2026 Biopharma Back to School Conference
Format: 1x1 meetings
Date: Thursday, September 10, 2026
Morgan Stanley 24th Annual Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, September 16, 2026
Time: 10:00 AM - 10:35 AM EST
The webcast of the Morgan Stanley fireside chat will be accessible on the investor section of Attovia's website. A replay of the webcast will be available for approximately 90 days following the conference.
About Attovia Therapeutics, Inc.
AttoviaTM is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using its ATTOBODYTM biparatopic biologics platform. Attovia's ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates.
Attovia's lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases; and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease. Attovia's other programs include highly innovative conditional 'AND' gated bispecific immune cell survival blockers and multispecifics.
Investor and Media Contact
Attovia Therapeutics
...
PJ Kelleher
LifeSci Advisors LLC
617-430-7579
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment